-chemical-structure-s8064.gif "Midostaurin (PKC412) | ≥99%(HPLC) | Selleck | PKC inhibitor")
Midostaurin (PKC412) | ≥99%(HPLC) | Selleck | PKC inhibitor
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
A) Effects of PKC412 inhibition of phospho-FLT3 in MOLM13-S and... | Download Scientific Diagram
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
Alliance -
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia | Leukemia
Kinase inhibition by PKC412 prevents epithelial sheet damage in autosomal dominant epidermolysis bullosa simplex via keratin and cell contact stabilization - ScienceDirect
Evolving Therapeutic Options for Acute Myeloid Leukemia
FDA grants Breakthrough Therapy status to PKC412
Frontiers | Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia | Bone Marrow Transplantation
Figures and data in Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy | eLife
Cancers | Free Full-Text | Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia | HTML
Evolving Therapeutic Options for Acute Myeloid Leukemia
Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram
CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML - Waldeck - 2020 - Molecular Oncology - Wiley Online Library
A) Comparison of rate of proliferation of MOLM13-S, MOLM13-R-PKC412... | Download Scientific Diagram
![PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b825a5d927ce38433166e20b17c67b5fa1f2f0b6/6-Table6-1.png "PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar")
PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar
Structure-activity relationship between PKC412 analogs and SYK... | Download Scientific Diagram
Midostaurin: a magic bullet that blocks mast cell expansion and activation - Annals of Oncology
Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells
Midostaurin (PKC412) | CAS:120685-11-2 | PKC inhibitor | High Purity | Manufacturer BioCrick
Midostaurin (PKC412) | Multi-targeted Protein Kinase Inhibitor | MedChemExpress
